Hostname: page-component-6766d58669-bp2c4 Total loading time: 0 Render date: 2026-05-18T06:07:35.941Z Has data issue: false hasContentIssue false
  • English
  • Français

Novel biomarker to detect perilmph leakage, CTP (Cochlin tomo-protein, an isoform of Cochlin)

Presenting Author: Tetsuo Ikezono

Published online by Cambridge University Press:  03 June 2016

Tetsuo Ikezono ,
Han Matsuda ,
Tomohiro Matsumura ,
Shinnichi Usami ,
Mamoru Suzuki ,
Kaoru Ogawa  and
Yasuhiro Kase
Tetsuo Ikezono
Affiliation:
Saitama Medical University Faculty Of Medicine, The PLF Study Group, Japan
Han Matsuda
Affiliation:
Department of Otorhinolaryngology, Saitama Medical University Faculty Of Medicine, The PLF Study Group, Japan
Tomohiro Matsumura
Affiliation:
Department of Boichemistry & Molecular Biology, Nippon Medical School
Shinnichi Usami
Affiliation:
Department of Otorhinolaryngology, Shinshu University, the Genetic And Anomalous Ear Diseases Study Group, Japan
Mamoru Suzuki
Affiliation:
Department of Otorhinolaryngology, Tokyo Medical University, the Peripheral Vestibular Disorder Research Committee, Japan
Kaoru Ogawa
Affiliation:
22. Department of Otorhinolaryngology, Keio University, the Acute Severe Hearing Loss Study Group, Japan
Yasuhiro Kase
Affiliation:
Department of Otorhinolaryngology, Saitama Medical University Faculty Of Medicine
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Learning Objectives: Perilymphatic fistula (PLF) is an abnormal connection between the inner and middle ear. A procedure for obtaining definite proof of a PLF remains elusive, and methods of diagnosis remain controversial. CTP is a novel biochemical marker that allows a definitive diagnosis of the etiology of PLF-related hearing loss and vestibular disorders. The science of PLF will be discussed in this talk.

Introduction: Numerous biomarkers for dizziness and hearingloss has been suggested including autoantibodies, inflammatory cytokines, CRP. Among these, CTP (Cochlin tomo-protein, an isoform of Cochlin), perilymph specific protein, is a novel and unique biomarker. We have reported a biochemical test for perilymph leakage detecting CTP in middle ear lavage (MEL, lavaging the middle ear cavity using 0.3 ml saline).

Methods: Recently we could establish a highly reliable ELISA-kit to detect CTP. The Japanese PLF diagnosis criterion is now based on the visual identification of the fistula (not a leakage) and/or detecting CTP. With a help of private clinical test enterprise (SRL inc.) in Japan, CTP test is widely available nationwide, in 170 hospitals.

Diagnostic Accuracy of the test is very high. If there is 2ul of leaked perilymph in the MEL, the test is positive. The diagnostic performance of the test has a high reliability, and the AUC in ROC analysis was greater than 0.90.

Results: The pattern of hearing loss of CTP positive PLF cases varies, including sudden onset, progressive, fluctuating or recurrent. In some patients with positive CTP test, dizziness is their chief complaint not hearing loss.

Conclusions: What We Could Learn from the CTP Test in hearing loss and/or dizzy patients. We believe CTP test will give the answer to the long-standing debate about the existence of PLF.